Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot clinical trial evaluating its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas. The study focused on individuals with metastatic or unresectable undifferentiated pleomorphic sarcoma/UPS and dedifferentiated liposarcoma/DDLPS who had failed at least one prior systemic treatment.

Among the first six evaluable patients, the therapy demonstrated a 50% objective response rate, with patients experiencing deep responses that improved over time despite a high baseline disease burden and multiple prior lines of therapy. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) highlighted a significant unmet medical need for these aggressive cancers, which affect over 8,000 patients annually across the US and Europe. Current second-line treatment options typically yield response rates of less than 5%, with median overall survival often falling under one year.

Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Medical experts involved in the trial noted that this one-time immunotherapy treatment showed unprecedented results for refractory patients who previously relied on chemotherapy with limited efficacy. The safety profile observed in the study was favorable and remained consistent with lifileucel’s performance in other solid tumors like melanoma and lung cancer. Following these results, Iovance plans to launch a single-arm registrational trial for second-line advanced UPS and DDLPS in Q2 2026.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally.

While we acknowledge the risk and potential of IOVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.